Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
Erica L. Mayer(Harvard University), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Arlene Chan(Curtin University), Debora Fumagalli(Université Libre de Bruxelles), Alistair Ring(National Health Service), Matthew P. Goetz(Mayo Clinic), Gábor Rubovszky(National Institute of Oncology), Tiffany A. Traina(Memorial Sloan Kettering Cancer Center), Florian Fitzal, Nicholas Zdenkowski(Lake Macquarie Private Hospital), Antonio C. Wolff(Johns Hopkins University), Otto Metzger(Dana-Farber Cancer Institute), Miguel Gil‐Gil(GEICAM – Spanish Breast Cancer Group), Julie Lemieux(Université Laval), Christian Fesl(Austrian Breast & Colorectal Cancer Study Group), Silvia Antolín(Universidade da Coruña), Manuel Ruíz‐Borrego(Hospital Universitario Virgen del Rocío), Magdalena Schwarz(Austrian Breast & Colorectal Cancer Study Group), Cynthia Huang Bartlett(Pfizer (United States)), María Koehler(Pfizer (United States)), Daniel Egle(Innsbruck Medical University), Harold J. Burstein(Dana-Farber Cancer Institute), Zbigniew Nowecki(The Maria Sklodowska-Curie National Research Institute of Oncology), Dongrui R. Lu(Pfizer (United States)), Patrick G. Morris(Memorial Sloan Kettering Cancer Center), Kathy D. Miller(Indiana University Health), Fernando Henao(Hospital Universitario Virgen Macarena), Eric P. Winer(University of Vermont), Alan P. Lyss(Missouri Baptist Medical Center), Carter DuFrane(Alliance Foundation Trials), Eleftherios P. Mamounas(Orlando Health), Georg Pfeiler(Medical University of Vienna), Hannes Fohler(Austrian Breast & Colorectal Cancer Study Group), Sibylle Loibl(Goethe University Frankfurt), Aleix Prat(Hospital Clínic de Barcelona), Amylou C. Dueck(Mayo Clinic in Arizona), Hope S. Rugo(City of Hope), Miguel Martín(Hospital General Universitario Gregorio Marañón), D. Mark Anderson(Regions Hospital), Stacy Moulder(The University of Texas MD Anderson Cancer Center), M. Bellet-Ezquerra(Vall d'Hebron Hospital Universitari), Marcus Vetter(University Hospital of Basel), Kathy Puyana Theall(Pfizer (United States)), Angela DeMichele(University of Pennsylvania)
Cited by 255
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.2k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k